Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment Centre of Excellence
VANCOUVER, British Columbia, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (CSE: SHRM) (the “Company” or “Champignon”) is expanding its rapid-onset
treatment service for major depressive disorder (“MDD”). Champignon will offer esketamine for the treatment of adults with MDD at its flagship clinic starting in September
2020. Ketamine was declared a breakthrough treatment for depression by the US Food and Drug Administration (“FDA”). In May 2020, Health Canada approved esketamine for the treatment
Champignon’s clinic, the Canadian Rapid Treatment Centre of Excellence (the “CRTCE”) is Canada's first multidisciplinary community clinic offering rapid-onset treatments for depression and is expected to be the first of its kind to provide this novel treatment for depression in Canada. The CRTCE is located in Mississauga, Ontario.
Depression is a leading cause of reduced income in Canada due to workplace disability: adults with MDD lose almost one month of work per year.1 Furthermore, depression, when co-occurring with heart disease, diabetes and other major chronic conditions, can worsen the course of these conditions and raise the risk for premature death.2
“The availability of esketamine at the CRTCE provides tremendous opportunity for adults across Canada affected by treatment-resistant depression to receive an effective, well-tolerated treatment. Moreover, this novel treatment works relatively faster than most conventional treatments for depression,” commented Dr. Roger McIntyre, Champignon’s Chief Executive Officer. “Esketamine has also been observed to help people with MDD when conventional treatments have been insufficient. This provides hope for people affected by MDD to have their symptoms improved and begin to function better again in their lives.”
Continuous Disclosure Review
As a further update, the Company continues to work with the British Columbia Securities Commission (“BCSC”) to complete its continuous disclosure review. The review relates to the Company's disclosure obligations since it became a reporting issuer on February 6, 2020, and includes a review of the disclosure surrounding certain recent acquisitions completed by the Company. The Company continues to fully cooperate with the BCSC to assist in completion of the review in a timely fashion.